Moderna kicks off Phase 1 trial of 3 different mRNA HIV vaccines
The trial is expected to run until mid-2023. By that point it is hoped one of the three formulations will have demonstrated robust immune responses and Phase 2 trials can commence.
From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.
The trial is expected to run until mid-2023. By that point it is hoped one of the three formulations will have demonstrated robust immune responses and Phase 2 trials can commence.
The Crib A’Glow can now be found in 500 hospitals across Nigeria and neighboring Ghana. It has already been used on 300,000 babies.
Clinical trials at Rice University are expected to begin in the next few months, after results on mice were described as “very exciting.”
The government is no longer granting environmental permits for open-pit mining projects, the Ministry of Energy, Natural Resources, Environment and Mines. It also plans to shut down open-pit mines already in operation.
The World Health Organization has estimated that more than 50 percent of vaccines go to waste every year, often due to the challenge in keeping vaccines at stable cold temperatures.
Any doctor in India found engaged in LGBTQ conversion therapy is now liable to be prosecuted for professional misconduct.
The University of Auckland team has spent more than a decade developing what they describe as a “bionic” pacemaker, a device designed to respond to the body’s signals in real-time.
Research from the University of Pennsylvania shows that attendance at follow-up appointments climbed among Black patients from 52% to 70% when telemedicine became a main mode for care visits.
The Carter Center began leading the global eradication effort in 1986, when the crippling and potentially deadly parasitic disease infected 3.5 million people.
The new study from the University of Cambridge involved 74 children with type 1 diabetes, aged one to seven, with subjects using the CamAPS FX artificial pancreas system for 16 weeks and showing promising results.